Abstract
Introduction: KRAS is altered in over 90% of pancreatic ductal adenocarcinomas (PDAC), yet the significance of specific KRAS alleles has not been well studied. Herein, we evaluate associations between KRAS variants and clinical outcomes.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have